Patent classifications
C07D277/32
MODULATORS OF THE INTEGRATED STRESS PATHWAY
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Process for preparing optically active 2,3-dihydrothiazolo[3,2-A]pyrimidin-4-ium compounds
The present invention relates to a process for preparing optically active compounds of formula X and intermediates thereof, ##STR00001##
wherein the variables of compound of formula X are as defined in the claims or the description.
Process for preparing optically active 2,3-dihydrothiazolo[3,2-A]pyrimidin-4-ium compounds
The present invention relates to a process for preparing optically active compounds of formula X and intermediates thereof, ##STR00001##
wherein the variables of compound of formula X are as defined in the claims or the description.
INHIBITORY MATERIAL AGAINST HUMAN BODY-DERIVED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE-DEPENDENT STEROID DEHYDROGENASE-LIKE, AND ANTICANCER AGENT COMPRISING SAME AS EFFECTIVE INGREDIENT OR PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR TREATMENT OF HYPERLIPIDEMIA
A nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like (NSDHL) inhibitor provided according to an aspect of the present invention can be used not only as an anticancer agent capable of overcoming resistance to EGFR-targeting anticancer agents, but also advantageously in the treatment of hyperlipidemia.
INHIBITORY MATERIAL AGAINST HUMAN BODY-DERIVED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE-DEPENDENT STEROID DEHYDROGENASE-LIKE, AND ANTICANCER AGENT COMPRISING SAME AS EFFECTIVE INGREDIENT OR PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR TREATMENT OF HYPERLIPIDEMIA
A nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like (NSDHL) inhibitor provided according to an aspect of the present invention can be used not only as an anticancer agent capable of overcoming resistance to EGFR-targeting anticancer agents, but also advantageously in the treatment of hyperlipidemia.
Process for preparing chiral 2,3-dihydrothiazolo[3,2-A] pyrimidin-4-ium compounds
The present invention relates to a process for preparing optically active compounds of formula X and intermediates thereof, ##STR00001##
wherein the variables of compound of formula X are as defined in the claims and the description.
SMALL MOLECULE MODULATORS OF THE BTB DOMAIN OF KEAP1
The present application relates to compounds of formula (I) or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).
PROCESS FOR PREPARING CHIRAL 2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM COMPOUNDS
The present invention relates to a process for preparing optically active compounds of formula X and intermediates thereof,
##STR00001##
wherein the variables of compound of formula X are as defined in the claims and the description.
Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst
An oxidative homocoupling method of synthesizing certain 2,2-bithiophenes from thiophenes using oxygen as the terminal oxidant is disclosed. In non-limiting examples, the method uses oxygen along with a catalytic system that includes palladium, an assistive ligand, and a non-palladium metal additive to catalyze one of the following reactions:
##STR00001##
Associated catalytic systems and compositions are also disclosed.
Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst
An oxidative homocoupling method of synthesizing certain 2,2-bithiophenes from thiophenes using oxygen as the terminal oxidant is disclosed. In non-limiting examples, the method uses oxygen along with a catalytic system that includes palladium, an assistive ligand, and a non-palladium metal additive to catalyze one of the following reactions:
##STR00001##
Associated catalytic systems and compositions are also disclosed.